AstraZeneca Sets Two NMEs Per Year As Metric Of R&D Success
Executive Summary
AstraZeneca is setting a goal of launching two new molecular entities each year, Exec VP-Global Drug Development Martin Nicklasson, PhD, said Feb. 10 at a drug development summit sponsored by R&D Directions in Phoenix
You may also be interested in...
Abbott To Cut Rx Development Costs In Half By Increasing Candidate Attrition
Abbott believes it can cut the cost of drug development in half by increasing the rate of attrition in the discovery phase, the company said Feb. 9 at a drug development summit sponsored by R&D Directions in Phoenix
Abbott To Cut Rx Development Costs In Half By Increasing Candidate Attrition
Abbott believes it can cut the cost of drug development in half by increasing the rate of attrition in the discovery phase, the company said Feb. 9 at a drug development summit sponsored by R&D Directions in Phoenix
Cancer Clinical Trial Sponsors Increasingly Favor Non-U.S. Sites, FDA Finds
The number of clinical trials used for registration of anticancer agents performed at least partially outside the U.S. has increased by approximately 50% in the last five years, FDA reported at the American Society of Clinical Oncology annual meeting